Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.53 |
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 4/20 | 0.40 |
| ▸ | TDO2 | P48775 | 2/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20120343 | 0.86 | MAPT (0.51) | MAPTKIF11ACHETDO2KCNH2 | |
| SCHEMBL22907251 | 0.86 | MAPT (0.51) | MAPTKIF11ACHETDO2KCNH2 | |
| SCHEMBL29547491 | 0.86 | MAPT (0.51) | MAPTKIF11ACHETDO2KCNH2 | |
| SCHEMBL20120342 | 0.86 | MAPT (0.51) | MAPTKIF11ACHETDO2KCNH2 | |
| SCHEMBL20233712 | 0.85 | MAPT (0.50) | MAPTKIF11ACHE | |
| SCHEMBL20129171 | 0.84 | MAPT (0.48) | MAPTKIF11ACHETDO2KCNH2 | |
| SCHEMBL20129172 | 0.84 | MAPT (0.48) | MAPTKIF11ACHETDO2KCNH2 | |
| SCHEMBL29547221 | 0.83 | MAPT (0.46) | MAPTKIF11ACHETDO2MKNK1 | |
| SCHEMBL20120229 | 0.83 | MAPT (0.46) | MAPTKIF11ACHETDO2MKNK1 | |
| SCHEMBL20120862 | 0.83 | MAPT (0.46) | MAPTKIF11ACHETDO2MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| WO-2018102067-A2 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | Arvinas, Inc. (US) | 2018-06-07 | — | — | WO | disclosed |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | MAPT 1/4885KIF11 2516/4885HRH3 3443/4885 |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | CRBN, VHL, UBQLN2 | MAPT 5/4885KIF11 2071/4885HRH3 3565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.